Valiant Laborato

Which are the latest news on Valiant Laborato?

Why is Valiant Laboratories Ltd falling/rising?

As of 05-Sep, Valiant Laboratories Ltd's stock price has risen to Rs 107.27, reflecting a 4.99% increase, supported by strong recent performance and a 67.98% gain over the past month, despite a decline in investor participation. The stock is trading above its moving averages and is close to its 52-week high, indicating strong momentum.

As of 05-Sep, Valiant Laboratories Ltd is experiencing a rise in its stock price, currently at Rs 107.27, which reflects an increase of 5.1 points or 4.99%. This upward movement is supported by several factors. Over the past week, the stock has gained 6.76%, significantly outperforming the Sensex, which has declined by 0.97%. In the last month, Valiant Laboratories has shown an impressive increase of 67.98%, while the Sensex has dropped by 2.44%. Year-to-date, the stock has risen by 53.44%, compared to a 10.21% decline in the Sensex.<BR><BR>Today's performance highlights that the stock opened with a gain of 4.99% and has been on a consecutive gain streak for the last three days, accumulating a total return of 15.74% during this period. Additionally, the stock is trading above its moving averages across various time frames, indicating strong momentum. It is also close to its 52-week high, just 3.25% away from Rs 110.76.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume dropping by 68.17% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the current rise is driven by strong performance metrics rather than high trading volume. Overall, the combination of strong recent returns, positive performance relative to the benchmark, and favorable trading conditions contributes to the rising stock price of Valiant Laboratories Ltd.

Who are in the management team of Valiant Laborato?

The management team of Valiant Laborato includes Velji Gogri (Chairman), Santosh S. Vora (Managing Director), Shantilal Shivji Vora (Director), Paresh Shashikant Shah (Executive Director), Sonal A Vira (Independent Director), Sandeep Gupta (Additional Non-Executive Director), and Saloni Mehta (Company Secretary & Compliance Officer). Each member contributes to the company's governance and operations.

The management team of Valiant Laborato includes the following key members:<BR><BR>1. **Velji Gogri** - Chairman & Independent Director<BR>2. **Santosh S. Vora** - Managing Director<BR>3. **Shantilal Shivji Vora** - Director<BR>4. **Paresh Shashikant Shah** - Executive Director<BR>5. **Sonal A Vira** - Independent Director<BR>6. **Sandeep Gupta** - Additional Non-Executive Director<BR>7. **Saloni Mehta** - Company Secretary & Compliance Officer<BR><BR>Each member plays a vital role in the governance and operational management of the company. If you need more specific information about their roles or contributions, feel free to ask!

What does Valiant Laborato do?

Valiant Laboratories Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 115 Cr and a net profit of 21 Cr for June 2026. It was established in 1980 and became a Public Limited Company in 2021.

Overview:<BR>Valiant Laboratories Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Valiant Laboratories Ltd was originally formed as a Partnership Firm under the name M/s. Bharat Chemicals on October 17, 1980. It converted into a Public Limited Company on August 16, 2021. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 115 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 21 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 532 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 33.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: -1.06% <BR>Price to Book: 1.76 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Valiant Laborato?

Valiant Laborato's peers include Shree Ganesh Rem, Bafna Pharma, Zim Laboratories, Kilitch Drugs, Albert David, Jenburkt Pharma, Haleos Labs Limi, Influx Health, and Infinium Pharma. Valiant Laborato has below average management and growth ratings, with a 1-year return of 12.10%.

Peers: The peers of Valiant Laborato are Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, Kilitch Drugs, Albert David, Jenburkt Pharma, Haleos Labs Limi, Influx Health., and Infinium Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Albert David, while Average management risk is found at Shree Ganesh Rem, Zim Laboratories, Kilitch Drugs, Haleos Labs Limi, and Influx Health., and the rest. Below Average management risk is noted for Bafna Pharma., Valiant Laborato, and Infinium Pharma. Growth is rated as Good for Kilitch Drugs and Influx Health., while Average growth is seen at Shree Ganesh Rem, Zim Laboratories, and the rest. Below Average growth is present at Bafna Pharma., Valiant Laborato, Albert David, Jenburkt Pharma, Haleos Labs Limi, and Infinium Pharma. Capital Structure is rated as Excellent for Shree Ganesh Rem and Albert David, Good for Kilitch Drugs and Valiant Laborato, Average for Bafna Pharma. and Zim Laboratories, and Below Average for Haleos Labs Limi and the rest.<BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 198.53%, while Influx Health. has the lowest at 0.00%. Valiant Laborato's 1-year return of 12.10% is higher than that of Influx Health. and Infinium Pharma. whose returns are also 0.00%. Additionally, Haleos Labs Limi and Jenburkt Pharma have negative six-month returns.

How big is Valiant Laborato?

As of 31st August, Valiant Laboratories Ltd has a market capitalization of 532.00 Cr, with net sales of 305.93 Cr and a net profit of 16.00 Cr reported in the latest four quarters.

As of 31st August, Valiant Laboratories Ltd has a market capitalization of 532.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest four quarters, Valiant Laboratories reported net sales of 305.93 Cr and a net profit of 16.00 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, showing shareholder's funds of 234.31 Cr and total assets of 400.86 Cr.

Should I buy, sell or hold Valiant Laboratories Ltd?

When is the next results date for Valiant Laboratories Ltd?

The next results date for Valiant Laboratories Ltd is August 10, 2026.

The next results date for Valiant Laboratories Ltd is scheduled for August 10, 2026.

Are Valiant Laboratories Ltd latest results good or bad?

Valiant Laboratories Ltd's latest results show strong revenue growth and a significant profit increase, but low operating margins and weak return on equity raise concerns about sustainability. Overall, the results are mixed, indicating potential but also underlying challenges for investors.

Valiant Laboratories Ltd's latest results present a mixed picture. On one hand, the company reported a significant net profit of ₹1.76 crores for Q4 FY26, which is a remarkable 124.93% increase compared to the previous quarter. Additionally, revenue growth was impressive, with net sales reaching ₹91.98 crores, reflecting a 75.33% quarter-on-quarter increase and a 59.16% year-on-year expansion.<BR><BR>However, despite these positive growth figures, the underlying profitability remains a concern. The operating margin is only 5.23%, which, while an improvement from the previous quarter's negative margin, is still quite low compared to industry standards. Furthermore, the return on equity (ROE) stands at a mere 1.60%, indicating weak capital efficiency and raising red flags about the company's ability to generate sustainable profits.<BR><BR>Moreover, the profit increase was largely driven by favorable tax adjustments rather than operational improvements, which suggests that the recent gains may not be sustainable. The company has also faced significant revenue erosion over the past two years, with a drastic decline from ₹333 crores in FY23 to ₹133 crores in FY25.<BR><BR>In summary, while Valiant Laboratories has shown some positive trends in the latest quarter, the persistent issues with profitability and capital efficiency indicate that the results are not entirely good. Investors should approach with caution, considering both the growth potential and the underlying challenges the company faces.

Is Valiant Laborato overvalued or undervalued?

As of November 17, 2025, Valiant Laborato is considered overvalued with a PE ratio of 85.70 and an EV to EBITDA of 61.56, significantly higher than its peers like Sun Pharma and Cipla, and has underperformed the Sensex with a year-to-date return of -27.77%.

As of 17 November 2025, the valuation grade for Valiant Laborato has moved from attractive to expensive, indicating a shift in perception regarding its market value. The company is currently considered overvalued, with a PE ratio of 85.70, an EV to EBITDA of 61.56, and a ROE of only 1.60%. These figures suggest that investors are paying a premium for earnings and cash flow, which may not be justified by the company's financial performance.<BR><BR>In comparison to its peers, Valiant Laborato's valuation metrics stand out significantly. For instance, Sun Pharma has a PE ratio of 36.69 and an EV to EBITDA of 24.22, while Cipla is valued more attractively with a PE of 22.81 and an EV to EBITDA of 16.14. The stark contrast in these ratios highlights that Valiant Laborato is trading at a much higher valuation relative to its industry counterparts. Additionally, the company's stock has underperformed the Sensex, with a year-to-date return of -27.77% compared to the Sensex's gain of 8.72%, reinforcing the notion that the stock may be overvalued in the current market environment.

How has been the historical performance of Valiant Laborato?

Valiant Laborato has experienced a significant decline in financial performance over the past three years, with net sales dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025, and operating profit turning from a profit of 39.95 Cr to a loss of 4.68 Cr. Total liabilities increased substantially, indicating growing financial challenges.

Answer:<BR>The historical performance of Valiant Laborato shows a significant decline in key financial metrics over the past three years, particularly in net sales and profitability.<BR><BR>Breakdown:<BR>Valiant Laborato's net sales have decreased from 333.91 Cr in March 2023 to 182.06 Cr in March 2024, and further down to 133.38 Cr in March 2025. Total operating income followed a similar trend, dropping from 333.91 Cr in March 2023 to 133.38 Cr in March 2025. The company's operating profit (PBDIT) also saw a drastic decline, moving from a profit of 39.95 Cr in March 2023 to a loss of 4.68 Cr in March 2025. Consequently, profit before tax shifted from 38.14 Cr in March 2023 to a loss of 1.51 Cr in March 2025, and profit after tax fell from 29.00 Cr to a loss of 2.20 Cr in the same period. The company's total liabilities increased from 212.97 Cr in March 2023 to 400.86 Cr in March 2025, while total assets rose from 212.97 Cr to 400.86 Cr, indicating a growing financial burden. Cash flow from operating activities decreased significantly from 56.00 Cr in March 2023 to 1.00 Cr in March 2025, and the net cash outflow in March 2025 was recorded at -6.00 Cr, reflecting ongoing financial challenges.

Is Valiant Laborato technically bullish or bearish?

As of August 6, 2025, Valiant Laborato's trend is mildly bullish due to daily moving averages, but mixed signals from the weekly MACD and Bollinger Bands suggest caution despite a bullish weekly RSI.

As of 6 August 2025, the technical trend for Valiant Laborato has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating a bullish signal. However, the weekly MACD remains bearish, and the Bollinger Bands are showing a mildly bearish trend on both weekly and monthly time frames. The weekly RSI is bullish, which supports the mildly bullish outlook, but the overall mixed signals from the MACD and Bollinger Bands suggest caution. The OBV is mildly bearish on the weekly but bullish on the monthly, indicating some divergence in volume trends. Overall, while there are bullish indicators, the strength is tempered by bearish signals in other areas.

Who are the top shareholders of the Valiant Laborato?

The top shareholder of Valiant Laborato is Dhanvallabh Ventures LLP, holding 46.84%. Other notable shareholders include L7 Hitech Private Limited with 2.23% and individual investors collectively owning 16.28%.

The top shareholders of Valiant Laborato include Dhanvallabh Ventures LLP, which holds the largest stake at 46.84%. The company is primarily controlled by its promoters, and there are no pledged promoter holdings. In terms of public shareholders, L7 Hitech Private Limited is the highest with a holding of 2.23%. Additionally, individual investors collectively own 16.28% of the company. There are also three foreign institutional investors (FIIs) holding a total of 0.64%.

Has Valiant Laborato declared dividend?

No Dividend History Available